Cargando…

Momelotinib decreased cancer stem cell associated tumor burden and prolonged disease-free remission period in a mouse model of human ovarian cancer

Despite a good initial response to front-line chemotherapy, majority of the ovarian cancer patients relapse with consecutive phases of recurrences; and nearly 60% die within 5 years due to the development of a chemoresistant disease. This study investigated whether inhibition of the Janus kinase 2 (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chan, Emily, Luwor, Rodney, Burns, Christopher, Kannourakis, George, Findlay, Jock K., Ahmed, Nuzhat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908273/ https://www.ncbi.nlm.nih.gov/pubmed/29682172 http://dx.doi.org/10.18632/oncotarget.24615

Ejemplares similares

Paclitaxel-Induced Src Activation Is Inhibited by Dasatinib Treatment, Independently of Cancer Stem Cell Properties, in a Mouse Model of Ovarian Cancer
por: Kadife, Elif, et al.
Publicado: (2019)

Coalition of Oct4A and β1 integrins in facilitating metastasis in ovarian cancer
por: Samardzija, Chantel, et al.
Publicado: (2016)

Knockdown of stem cell regulator Oct4A in ovarian cancer reveals cellular reprogramming associated with key regulators of cytoskeleton-extracellular matrix remodelling
por: Samardzija, Chantel, et al.
Publicado: (2017)

A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer
por: Samardzija, Chantel, et al.
Publicado: (2015)

Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden
por: Abubaker, Khalid, et al.
Publicado: (2014)

The Many Facets of Metzincins and Their Endogenous Inhibitors: Perspectives on Ovarian Cancer Progression
por: Escalona, Ruth M., et al.
Publicado: (2018)

Expression of TIMPs and MMPs in Ovarian Tumors, Ascites, Ascites-Derived Cells, and Cancer Cell Lines: Characteristic Modulatory Response Before and After Chemotherapy Treatment
por: Escalona, Ruth M., et al.
Publicado: (2022)

Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden
por: Abubaker, Khalid, et al.
Publicado: (2014)

Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden
por: Abubaker, Khalid, et al.
Publicado: (2013)

Unique proteome signature of post-chemotherapy ovarian cancer ascites-derived tumor cells
por: Ahmed, Nuzhat, et al.
Publicado: (2016)

TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells
por: Escalona, Ruth M., et al.
Publicado: (2020)

Isolation and Characterization of Tumor Cells from the Ascites of Ovarian Cancer Patients: Molecular Phenotype of Chemoresistant Ovarian Tumors
por: Latifi, Ardian, et al.
Publicado: (2012)

Knock down of TIMP-2 by siRNA and CRISPR/Cas9 mediates diverse cellular reprogramming of metastasis and chemosensitivity in ovarian cancer
por: Escalona, Ruth M., et al.
Publicado: (2022)

The attributes of plakins in cancer and disease: perspectives on ovarian cancer progression, chemoresistance and recurrence
por: Wesley, Tamsin, et al.
Publicado: (2021)

Neuronal transcription factor Brn-3a(l) is over expressed in high-grade ovarian carcinomas and tumor cells from ascites of patients with advanced-stage ovarian cancer
por: Ahmed, Nuzhat, et al.
Publicado: (2010)

Momelotinib: an emerging treatment for myelofibrosis patients with anemia
por: Chifotides, Helen T., et al.
Publicado: (2022)

Attributes of Oct4 in stem cell biology: perspectives on cancer stem cells of the ovary
por: Samardzija, Chantel, et al.
Publicado: (2012)

Ovarian Cancer, Cancer Stem Cells and Current Treatment Strategies: A Potential Role of Magmas in the Current Treatment Methods
por: Ahmed, Nuzhat, et al.
Publicado: (2020)

Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis
por: Pardanani, A, et al.
Publicado: (2015)

Momelotinib therapy for myelofibrosis: a 7-year follow-up
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Momelotinib is a highly potent inhibitor of FLT3-mutant AML
por: Azhar, Mohammad, et al.
Publicado: (2022)

PB2183: TRANSFUSION-RELATED COST OFFSETS AND TIME BURDEN IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH MOMELOTINIB (MMB) VS DANAZOL (DAN)
por: Masarova, Lucia, et al.
Publicado: (2023)

Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies
por: Mesa, Ruben A., et al.
Publicado: (2023)

P1062: INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS
por: Palandri, Francesca, et al.
Publicado: (2023)

Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis
por: Mesa, Ruben, et al.
Publicado: (2022)

Ovarian cancer disease burden decreased in the United States from 1975 to 2018: A joinpoint and age-period-cohort analysis
por: He, Jiahui, et al.
Publicado: (2023)

Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial–mesenchymal transition interlinked with reprogrammed metabolism
por: Leung, Dilys, et al.
Publicado: (2022)

P1044: REDUCTION IN RED BLOOD CELL TRANSFUSION BURDEN: A NOVEL LONGITUDINAL TIME-DEPENDENT ANALYSIS IN PATIENTS WITH TRANSFUSION-DEPENDENT MYELOFIBROSIS TREATED WITH MOMELOTINIB
por: Harrison, Claire, et al.
Publicado: (2023)

Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date
por: Bassiony, Sarah, et al.
Publicado: (2020)

P1057: INDIRECT TREATMENT COMPARISONS OF MOMELOTINIB VS PACRITINIB SAFETY AND ANEMIA OUTCOMES IN PATIENTS WITH MYELOFIBROSIS
por: Masarova, Lucia, et al.
Publicado: (2023)

Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials
por: Kiladjian, Jean-Jacques, et al.
Publicado: (2023)

Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials
por: Verstovsek, Srdan, et al.
Publicado: (2023)

Predicting Ovarian-Cancer Burden in Catalonia by 2030: An Age–Period–Cohort Modelling
por: Peremiquel-Trillas, Paula, et al.
Publicado: (2022)

Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures
por: Singer, Jack W., et al.
Publicado: (2019)

Blocking Muscarinic Receptor 3 Attenuates Tumor Growth and Decreases Immunosuppressive and Cholinergic Markers in an Orthotopic Mouse Model of Colorectal Cancer
por: Kuol, Nyanbol, et al.
Publicado: (2022)

Precision Medicine: An Optimal Approach to Patient Care in Renal Cell Carcinoma
por: Sharma, Revati, et al.
Publicado: (2022)

Prolonged Remission of Psoriasis with Azathioprine Pulse Therapy
por: Gupta, Ramji
Publicado: (2015)

A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer
por: Padda, Sukhmani K., et al.
Publicado: (2021)

In Vitro and In Silico Analysis of Epithelial-Mesenchymal Transition and Cancer Stemness as Prognostic Markers of Clear Cell Renal Cell Carcinoma
por: Sharma, Revati, et al.
Publicado: (2023)

The ovarian reserve is depleted during puberty in a hormonally driven process dependent on the pro-apoptotic protein BMF
por: Liew, Seng H, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_c7l6dvge4g4dhubaggokub9tcm